Pentagon Issues New Guidance for Mandatory Testosterone Screening

The Pentagon has issued new guidance for mandatory testosterone deficiency screening for male service members over the age of 30 in active duty and reserve components. This directive follows the temporary rescission of similar guidelines two weeks prior, which were described as a draft that had been "inadvertently" posted.

The newly released guidance aims to establish uniform screening and treatment pathways across the Defense Health Agency. "By proactively identifying and treating suboptimal hormone levels, the Department continues to invest in the health of its warfighters, strengthen their performance, and maximize force readiness," said Sean Parnell, chief Pentagon spokesman.

Under the clinical practice guidelines, all male service members over 30 will undergo a "structured symptom and risk assessment." Those under 30 may be screened upon request. The screening process involves measuring testosterone levels on two separate mornings while the service member is fasting. This will be accompanied by an LH/FSH blood test panel to assess luteinizing and follicle-stimulating hormone levels. If total testosterone levels fall within a certain range, free testosterone will also be tested.

Guidance for female service members regarding hormonal health is still under review and will be posted upon approval. Previously, draft guidelines had indicated that female service members should be asked about fatigue and disrupted menstrual cycles that could indicate hormonal dysregulation.

This initiative marks a significant shift, as testosterone testing has not previously been a part of the military's annual health assessments, which typically focus on vaccinations, vision, and hearing tests. Service members have had access to testosterone testing and replacement therapy through Tricare, but the screenings were not standardized.

Low testosterone levels have been a growing concern within the military, particularly in high-stress environments like special operations, where extreme physical demands and insufficient caloric intake may impact hormone levels. While research is ongoing, the American Urological Association (AUA) estimates that between 4.0 million and 13.8 million men in the U.S. had testosterone deficiency in 2023. However, the AUA also notes that the prevalence of the issue is not fully clear and thresholds for deficiency can vary. Testosterone issues are more common in older men, as well as those with diabetes or obesity.

Some medical professionals express concern that the online popularity of "low-T" may create an exaggerated perception of the problem. According to the AUA, testosterone testing and prescribing have tripled in recent years, yet up to 25% of men receiving testosterone therapy may not have their levels properly tested. The AUA previously stated that a diagnosis requires both symptoms and signs of low testosterone, along with at least two separate early-morning total testosterone measurements indicating low levels.